New Protein Platform Grows HIV-Fighting Immune Cells That Standard Methods Can't Produce | Research

The takeaway

A novel protein scaffold called Immuno-STAT successfully expanded potent HIV-specific killer T cells from the naive immune repertoire, outperforming conventional dendritic cell approaches.

Expanded where DCs failed
Immuno-STAT generated HIV-specific SL9 CD8+ T cells from naive repertoire that conventional dendritic cell methods could not activate

What the researchers found

Researchers developed Immuno-STAT (IST), a protein scaffold that delivers peptide-specific T cell receptor activation plus CD28 costimulatory signals to expand HIV-specific killer T cells from the naive immune repertoire. The IST platform succeeded where conventional dendritic cell methods failed: it expanded naive SL9-specific CD8+ T cells (targeting a key HIV epitope) that dendritic cells could not stimulate.

The IST-generated T cells showed potent cytotoxicity against HIV-infected targets, diverse T cell receptor clonotypes (suggesting broad coverage), memory-differentiated phenotypes, and polyfunctionality — all critical qualities for an effective HIV-targeting immune response.

Why it matters

A functional HIV cure remains one of medicine's biggest challenges. Current adoptive cell therapy approaches are limited by the difficulty of expanding HIV-specific T cells outside the body. This new peptide-based platform (IST) overcomes that barrier by activating naive T cells that conventional methods can't reach, potentially enabling the generation of targeted immune responses against conserved HIV epitopes and immune escape variants.

The numbers in context

Targets 2 epitopes: HIV SL9 + melanoma MART-1 · Polyfunctional CD8+ T cells generated · Diverse TCR clonotypes · IST succeeded where DC-based expansion failed for SL9

How the study worked

Proof-of-concept study developing the Immuno-STAT protein scaffold platform. Researchers designed dimeric proteins that present peptide epitopes (HIV SL9 or melanoma MART-1) with optional CD28 costimulation to naive CD8+ T cells ex vivo. They compared IST-expanded T cells against those generated by conventional peptide-loaded dendritic cells, assessing expansion efficiency, cytotoxicity, TCR diversity, polyfunctionality, and memory phenotype.

Who was studied

In vitro study using human naive CD8+ T cells expanded against HIV and melanoma peptide epitopes

What this study cannot tell us

This is an in vitro proof-of-concept study — no human patients were treated with IST-generated T cells. The approach has not been tested in vivo for efficacy against HIV infection. The scalability and safety profile of adoptive transfer of these cells remains unknown. Manufacturing complexity and cost of the IST platform are not addressed.

How to read the evidence

This is an in vitro proof-of-concept study demonstrating a new technology platform. While the results are promising and well-characterized, no patients have been treated and no in vivo efficacy data exists yet.

When this study was published

Published in 2025, this represents cutting-edge work in peptide-based immunotherapy for HIV, an area of intense research activity.

The bigger picture

Peptide-based immunotherapy is a growing frontier in both HIV and cancer treatment. This study demonstrates that rationally designed protein scaffolds can present peptide epitopes more effectively than natural antigen-presenting cells for certain targets. The modular IST platform could be adapted to target different HIV epitopes, predicted viral escape mutations, or cancer antigens — making it a potentially versatile tool across immunotherapy applications.

Questions still open

Will IST-generated HIV-specific T cells control viral replication when transferred into people living with HIV?
Can the IST platform be scaled to target multiple conserved HIV epitopes simultaneously, reducing the chance of viral escape?
How does the cost and manufacturing complexity of IST compare to other adoptive cell therapy approaches like CAR-T cells?

Common questions

What is adoptive cell therapy for HIV?

Adoptive cell therapy involves taking immune cells from a patient, growing and training them in the lab to specifically target HIV-infected cells, then infusing them back into the patient. The goal is to create a powerful army of HIV-killing immune cells that could control the virus without daily medication — potentially contributing to a functional cure.

Why is it hard to grow HIV-specific T cells in the lab?

Standard methods use dendritic cells (natural immune cells) loaded with HIV peptides to stimulate T cell growth. But for some HIV targets, this approach simply doesn't work well with naive T cells — the immune cells that haven't encountered HIV before. The Immuno-STAT platform solves this by delivering the activation signals in a more controlled, modular way that can reach T cells that natural methods miss.

Read the original research

T-cell receptor/CD28-targeted immunotherapeutics selectively drive naive T-cell expansion to generate functional HIV-specific responses.

Journal of virology, 99(9), e0018825

View on PubMed ↗Publisher’s paper ↗

Citation

Mueller, April L; Lamcaj, Sara; Garforth, Scott; Hiner, Christopher; Woodley, Darien; Paraiso, Kitt; Mi, Tian; Low, Simon; Youngblood, Ben; Almo, Steven C; Goldstein, Harris. (2025). T-cell receptor/CD28-targeted immunotherapeutics selectively drive naive T-cell expansion to generate functional HIV-specific responses.. Journal of virology, 99(9), e0018825. https://doi.org/10.1128/jvi.00188-25